Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Download Data

Vor Biopharma Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) for the quarter ending September 20, 2024

Vor Biopharma Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) is NA for the quarter ending September 20, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Vor Biopharma Inc Accounts Payable Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
Vor Biopharma Inc Accounts Payable Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
Vor Biopharma Inc Accounts Payable Turnover Ratio for the quarter ending March 31, 2021 was 0.00, a 0.00% change year over year.
Vor Biopharma Inc Accounts Payable Turnover Ratio for the quarter ending March 31, 2020 was 0.00.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends